Loncastuximab Tesirine + Mosunetuzumab for Lymphoma

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: City of Hope Medical Center

Must not be taking: Steroids, Immunosuppressants, HAART, others

Disqualifiers: HIV, Hepatitis, Autoimmune, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 2 years post-last dose

36 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the effectiveness of a new combination of treatments for individuals with diffuse large B-cell lymphoma, a type of blood cancer that has recurred or resisted previous treatments. The study combines two drugs: loncastuximab tesirine, an antibody-drug conjugate that targets and attacks cancer cells, and mosunetuzumab, a monoclonal antibody that helps prevent cancer growth and spread. Suitable candidates for this trial are those who have this specific lymphoma and have tried at least one other treatment without success. As a Phase 2 trial, the study measures the treatment's effectiveness in an initial, smaller group, offering a chance to benefit from innovative therapies.

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, if you are on systemic steroid therapy for lymphoma symptom control, it must be reduced to 20 mg/day prednisone or equivalent. It's best to discuss your specific medications with the study team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that loncastuximab tesirine is safe and generally well-tolerated. In earlier studies, patients experienced manageable side effects when treated with loncastuximab tesirine. This treatment specifically targets cancer cells to deliver a toxic agent that kills them. The FDA has even granted fast-track approval for other conditions, supporting its safety.

Mosunetuzumab also targets and disrupts cancer cell growth. While specific safety data on using loncastuximab tesirine and mosunetuzumab together is still being collected, past research on each treatment alone shows promising safety. Both have been tested in patients with similar types of lymphoma, suggesting they might be well-tolerated when combined.

Overall, existing data suggests these treatments are safe, but ongoing research will continue to monitor and confirm this. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about the combination of Loncastuximab Tesirine and Mosunetuzumab for treating lymphoma because these treatments offer a novel approach compared to traditional therapies like chemotherapy and radiation. Loncastuximab Tesirine is an antibody-drug conjugate that specifically targets cancer cells and delivers a potent cytotoxic agent directly to them, potentially reducing damage to healthy cells. Mosunetuzumab is a bispecific antibody that simultaneously binds to T-cells and cancer cells, helping the immune system attack the cancer more effectively. Together, these treatments could offer a more targeted and potentially more effective option for patients with lymphoma.

What evidence suggests that this trial's treatments could be effective for diffuse large B-cell lymphoma?

This trial will evaluate the combination of loncastuximab tesirine and mosunetuzumab for treating diffuse large B-cell lymphoma (DLBCL). Research has shown that using loncastuximab tesirine with mosunetuzumab may effectively treat DLBCL. Loncastuximab tesirine targets cancer cells with a specific marker called CD19 and delivers a toxic substance to kill them. Mosunetuzumab may help prevent cancer cells from growing and spreading. Early studies indicate that these treatments, when combined, have led to positive outcomes in patients whose DLBCL has returned or not responded to previous treatments. Loncastuximab tesirine is already approved for treating relapsed DLBCL, supporting its potential effectiveness when used with mosunetuzumab. ^{1 4 6 7 8}

Who Is on the Research Team?

Swetha Kambhampati

Principal Investigator

City of Hope Medical Center

Are You a Good Fit for This Trial?

Adults (18+) with relapsed or refractory diffuse large B-cell lymphoma, including certain subtypes, who have had at least one prior therapy can join. Participants must be in good physical condition (ECOG <=2), not pregnant or breastfeeding, and willing to use birth control. They should not have active infections like HIV or hepatitis, autoimmune diseases needing treatment, recent major surgery unrelated to diagnosis, or a history of certain severe reactions to similar drugs.

Inclusion Criteria

I am a woman who can have children and my pregnancy test is negative.

Documented informed consent of the participant and/or legally authorized representative

My white blood cell count is healthy or can be with treatment.

Exclusion Criteria

Concomitant investigational therapy

I haven't had radiotherapy in the last 2 weeks.

I have had a solid organ transplant.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Safety Lead-In

Evaluate the safety and tolerability of loncastuximab tesirine plus mosunetuzumab

Up to 30 days post-last dose

Multiple visits for IV administration and monitoring

Treatment

Patients receive loncastuximab tesirine and mosunetuzumab intravenously

Up to 2 years post-last dose

Regular visits for IV administration, PET/CT scans, and biopsies

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 2 years post-last dose

What Are the Treatments Tested in This Trial?

Interventions

• Loncastuximab Tesirine
• Mosunetuzumab

Trial Overview The trial is testing the combination of two drugs: Loncastuximab Tesirine and Mosunetuzumab for treating patients whose diffuse large B-cell lymphoma has returned after treatment or hasn't responded. The study will assess the safety and effectiveness of this drug duo.

How Is the Trial Designed?

Group I: Treatment (oncastuximab tesirine, mosunetuzumab) Experimental Treatment 6 Interventions

Patients receive loncastuximab tesirine IV and mosunetuzumab IV on study. Patients also undergo PET/CT scan, biopsy, and collection of blood samples on study.

Loncastuximab Tesirine is already approved in United States, European Union for the following indications:

Approved in United States as Zynlonta for:

• Diffuse large B-cell lymphoma (DLBCL)
• DLBCL arising from low-grade lymphoma
• High-grade B-cell lymphoma

Approved in European Union as Zynlonta for:

• Diffuse large B-cell lymphoma (DLBCL)
• DLBCL arising from low-grade lymphoma
• High-grade B-cell lymphoma

Who Is Running the Clinical Trial?

City of Hope Medical Center

Lead Sponsor

Trials

614

Recruited

1,924,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

Loncastuximab tesirine is an antibody-drug conjugate that targets B cell lymphomas, specifically approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of treatment.

The drug works by using an anti-CD19 antibody to deliver a DNA-alkylating agent directly to B cells, enhancing its efficacy in targeting cancer cells while minimizing damage to healthy cells.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Loncastuximab Tesirine: First Approval. Lee, A.[2021]

In a phase 1 study involving 183 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, loncastuximab tesirine demonstrated a promising overall response rate of 45.6%, with 26.7% achieving complete responses, indicating its potential as an effective treatment option.

The study established a recommended dose of 150 µg/kg for phase 2 trials, with an acceptable safety profile characterized by manageable hematologic toxicities, suggesting that loncastuximab tesirine could be a viable alternative to current therapies for this challenging patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Hamadani, M., Radford, J., Carlo-Stella, C., et al.[2022]

In a study of 11 girls with severe childhood-onset systemic lupus erythematosus (SLE), rituximab treatment led to remission in 6 out of 8 patients with lupus nephritis and both patients with autoimmune cytopenia, indicating its potential efficacy as a co-therapy.

However, the study also reported that 45% of patients experienced severe adverse events, highlighting the need for caution and further research to better understand the safety profile of rituximab in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Rituximab therapy for childhood-onset systemic lupus erythematosus. Willems, M., Haddad, E., Niaudet, P., et al.[2015]

Mosunetuzumab, a bispecific antibody targeting CD20 and CD3, has received conditional approval in the EU for treating adults with relapsed or refractory follicular lymphoma after at least two prior therapies.

This approval marks a significant milestone in the development of mosunetuzumab, highlighting its potential as a new treatment option for patients with difficult-to-treat lymphoma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mosunetuzumab: First Approval. Kang, C.[2022]

In a study of 30 patients with recently diagnosed systemic lupus erythematosus (SLE) treated with belimumab for 6 months, significant improvements were observed in key laboratory markers, including increased white blood cell counts and hemoglobin levels, and decreased disease activity scores.

Belimumab was found to be safe and effective, potentially reducing the need for glucocorticoids and improving anemia, with minimal adverse reactions reported.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Short-term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus. Wu, C., Gong, B.[2022]

In a study involving 80 patients from the LOTIS-2 trial, loncastuximab tesirine (Lonca) demonstrated a significantly higher overall response rate (53.4%) compared to chemoimmunotherapy (CIT) treatments (40.3%) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Lonca also showed improved overall survival, with a median survival of 10.8 months compared to 6.4 months for CIT, indicating it may be a more effective treatment option for patients with R/R DLBCL.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. Hamadani, M., Chen, L., Song, Y., et al.[2022]

In a phase 2 trial involving 145 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), loncastuximab tesirine demonstrated a significant overall response rate of 48.3%, indicating its effectiveness as a treatment option for this challenging patient population.

The treatment was associated with an acceptable safety profile, with serious adverse events occurring in 39% of patients, but none were directly linked to loncastuximab tesirine, suggesting it may be a safe option for heavily pretreated patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Caimi, PF., Ai, W., Alderuccio, JP., et al.[2021]

Loncastuximab tesirine-lpyl, an anti-CD19 antibody-drug conjugate, has shown a 48.3% overall response rate in patients with relapsed, refractory diffuse large B-cell lymphoma during the phase II LOTIS-2 trial, indicating its efficacy as a treatment option.

The drug demonstrated a tolerable safety profile with common side effects including neutropenia and thrombocytopenia, and no new safety concerns were identified in the phase II trial, suggesting it is safe for further testing in various non-Hodgkin lymphoma subtypes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Loncastuximab tesirine for diffuse large B-cell lymphoma. Zurko, J., Hamadani, M.[2021]

Loncastuximab tesirine, an antibody-drug conjugate targeting CD19, has shown promising efficacy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with overall response rates of 42.3% in LOTIS-1 and 48.3% in LOTIS-2 trials.

The treatment has an acceptable safety profile, with common side effects including anemia, neutropenia, fatigue, and nausea, making it a viable option for patients who have not responded to previous therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. Xu, B.[2022]

In a study involving 364 patients with systemic lupus erythematosus (SLE), long-term treatment with belimumab combined with standard therapy demonstrated a stable or declining incidence of adverse events over 4 years, indicating a favorable safety profile.

The most common side effects were mild, such as arthralgia and upper respiratory infections, and serious infusion reactions were rare, suggesting that belimumab can be safely administered for extended periods in SLE patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Merrill, JT., Ginzler, EM., Wallace, DJ., et al.[2013]

Loncastuximab tesirine-lpyl, an anti-CD19 antibody drug, has been safely administered at full doses to patients with relapsed/refractory DLBCL despite their severe hepatic dysfunction, suggesting potential efficacy in this challenging patient population.

The cases presented highlight the need for further investigation into the safety and dosing guidelines of loncastuximab tesirine-lpyl in patients with moderate to severe liver impairment, as current guidance from the manufacturer is unclear.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction. Baek, GT., Huang, IJ., Gopal, AK.[2023]

Rituximab, a B cell-targeted biologic used for autoimmune diseases, has a low incidence of serious infections, but there is a rare risk of progressive multifocal leucoencephalopathy, occurring in about 5 out of 100,000 patients, with no proven causal link established.

Repeated use of rituximab can lead to hypogammaglobulinaemia, which increases the risk of serious infections, highlighting the need for careful monitoring of patients undergoing this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Md Yusof, MY., Vital, EM., Buch, MH.[2022]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT05672251

Study Details | NCT05672251 | Loncastuximab Tesirine ... This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12159156/

QSP modeling of loncastuximab tesirine with T-cell-dependent ... The model-simulated tumor growth outcomes were consistent with relative response rates reported for the three agents, indicating that the ...

3. ir.adctherapeutics.com ir.adctherapeutics.com/press-releases/press-release-details/2024/ADC-Therapeutics-Announces-Updates-on-LOTIS-7-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Glofitamab-or-Mosunetuzumab-in-Patients-with-RelapsedRefractory-B-cell-Non-Hodgkin-Lymphoma/default.aspx

ADC Therapeutics Announces Updates on LOTIS-7 ... A Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab.

4. cancernetwork.com cancernetwork.com/view/loncastuximab-tesirine-combo-demonstrates-early-efficacy-in-r-r-dlbcl

Loncastuximab Tesirine Combo Demonstrates Early ... Loncastuximab tesirine-lpyl (Zynlonta) plus glofitamab (Columvi) demonstrated early efficacy outcomes in a small cohort of patients with ...

5. ashpublications.org ashpublications.org/blood/article/140/4/303/485279/The-antibody-drug-conjugate-loncastuximab-tesirine

The antibody-drug conjugate loncastuximab tesirine for the ... Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL.

6. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/37646659/

long-term efficacy and safety from the phase II LOTIS-2 study Lonca continued to demonstrate durable, long-term responses with manageable safety and tolerability in patients with CR.

7. ir.adctherapeutics.com ir.adctherapeutics.com/press-releases/press-release-details/2025/ADC-Therapeutics-Announces-Updated-Data-from-LOTIS-7-Clinical-Trial-Presented-at-the-European-Hematology-Association-2025-Congress/default.aspx

ADC Therapeutics Announces Updated Data from LOTIS-7 ... ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval ...

8. onclive.com onclive.com/view/loncastuximab-tesirine-plus-glofitamab-shows-early-safety-and-efficacy-in-r-r-dlbcl

Loncastuximab Tesirine Plus Glofitamab Shows Early ... Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.